• Inborn errors of metabolism

Glassia Generic Name & Formulations

General Description

Alpha1-proteinase inhibitor (human) 1g/vial; soln for IV infusion; preservative- and latex-free.

How Supplied

Single-use vial (50mL)—1 (w. a filter needle)

Generic Availability


Glassia Indications


For chronic augmentation and maintenance therapy in adults with clinical evidence of emphysema due to severe alpha1-proteinase inhibitor (Alpha1-PI) deficiency.

Limitations of Use

Effect of augmentation therapy on pulmonary exacerbations and progression of emphysema in Alpha1-PI deficiency has not been conclusively demonstrated in clinical trials. Data demonstrating the long-term effects of chronic augmentation and maintenance therapy are not available. Not for treating lung disease in patients whom severe Alpha1-PI deficiency has not been established.

Glassia Dosage and Administration


Should be administered by healthcare provider or self-administered at home after appropriate training. Give by IV infusion at a max rate of 0.2mL/kg/min. 60mg/kg once weekly. Monitor the infusion rate closely during administration and for signs of infusion-related reactions.


Not established.

Glassia Contraindications


IgA deficient patients with antibodies against IgA.

Glassia Boxed Warnings

Not Applicable

Glassia Warnings/Precautions


Have epinephrine and/or other supportive therapy available. Discontinue if hypersensitivity reactions occur and treat appropriately. Contains human plasma; monitor for possible infection transmission (eg, viruses, Creutzfeldt-Jakob disease agent). Pregnancy. Nursing mothers.

Glassia Pharmacokinetics

See Literature

Glassia Interactions

Glassia Adverse Reactions

Adverse Reactions

Headache, upper respiratory tract infection, cough, sinusitis, chest discomfort, dizziness, hepatic enzyme increased.

Glassia Clinical Trials

See Literature

Glassia Note

Not Applicable

Glassia Patient Counseling

See Literature